ImmunoGen, Inc. (IMGN) was a big mover last session, as its shares rose nearly 9% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company, as the stock is now down over 11%.
In the last 30 days, the company has not seen any estimate revision while the Zacks Consensus Estimate moved slightly higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
ImmunoGen currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Better-ranked stocks in the med-drugs industry include Enanta Pharmaceuticals, Inc. (ENTA), Endo International plc (ENDP) and Ironwood Pharmaceuticals, Inc. (IRWD). All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment